Treatment with angiotensin receptor–neprilysin inhibitors (ARNI) and SGLT2 inhibitors lowered serum UA concentrations with improved outcomes in patients with HF [58,64]. The gene discussed is SLC5A2; the disease is hydrops fetalis.